Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability

por Bijoux Leist, Judith, Leist, Thomas P.
Publicado 2022

Involvement of β-chemokines in the development of inflammatory demyelination

por Banisor, Ileana, Leist, Thomas P, Kalman, Bernadette
Publicado 2005

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

por Reder, Anthony T, Stuve, Olaf, Tankou, Stephanie K, Leist, Thomas P
Publicado 2022

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment

por Kalatskaya, Irina, Giovannoni, Gavin, Leist, Thomas, Cerra, Joseph, Boschert, Ursula, Rolfe, P. Alexander
Publicado 2023

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

por Montalban, Xavier, Leist, Thomas P., Cohen, Bruce A., Moses, Harold, Campbell, Jackie, Hicking, Christine, Dangond, Fernando
Publicado 2018

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

por Rammohan, Kottil, Coyle, Patricia K., Sylvester, Elke, Galazka, Andrew, Dangond, Fernando, Grosso, Megan, Leist, Thomas P.
Publicado 2020

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

por Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula
Publicado 2019

N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study

por Monti, Daniel A., Zabrecky, George, Leist, Thomas P., Wintering, Nancy, Bazzan, Anthony J., Zhan, Tingting, Newberg, Andrew B.
Publicado 2020

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

por Giovannoni, Gavin, Galazka, Andrew, Schick, Regina, Leist, Thomas, Comi, Giancarlo, Montalban, Xavier, Damian, Doris, Dangond, Fernando, Cook, Stuart
Publicado 2020

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

por Oh, Jiwon, Walker, Bryan, Giovannoni, Gavin, Jack, Dominic, Dangond, Fernando, Nolting, Axel, Aldridge, Julie, Lebson, Lori A, Leist, Thomas P
Publicado 2021

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

por Giovannoni, Gavin, Coyle, Patricia K., Vermersch, Patrick, Walker, Bryan, Aldridge, Julie, Nolting, Axel, Galazka, Andrew, Lemieux, Caroline, Leist, Thomas P.
Publicado 2021

Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

por Coyle, Patricia K, Cohen, Bruce A, Leist, Thomas, Markowitz, Clyde, Oleen-Burkey, MerriKay, Schwartz, Marc, Tullman, Mark J, Zwibel, Howard
Publicado 2014

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

por Freedman, Mark S, Leist, Thomas P, Comi, Giancarlo, Cree, Bruce AC, Coyle, Patricia K, Hartung, Hans-Peter, Vermersch, Patrick, Damian, Doris, Dangond, Fernando
Publicado 2017

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

por Weinstock-Guttman, Bianca, Bermel, Robert, Cutter, Gary, Freedman, Mark S, Leist, Thomas P, Ma, Xiaoye, Kile, Deidre, Musch, Bruno, Reder, Anthony T, Wolinsky, Jerry S
Publicado 2021

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

por De Stefano, Nicola, Sormani, Maria Pia, Giovannoni, Gavin, Rammohan, Kottil, Leist, Thomas, Coyle, Patricia K, Dangond, Fernando, Keller, Birgit, Alexandri, Nektaria, Galazka, Andrew
Publicado 2021

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

por Freedman, Mark S, Coyle, Patricia K, Comi, Giancarlo, L Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Galazka, Andrew, Jack, Dominic, Lebson, Lori A, Leist, Thomas P
Publicado 2021

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

por Giovannoni, Gavin, Boyko, Alexey, Correale, Jorge, Edan, Gilles, Freedman, Mark S, Montalban, Xavier, Rammohan, Kottil, Stefoski, Dusan, Yamout, Bassem, Leist, Thomas, Aydemir, Aida, Borsi, Laszlo, Verdun di Cantogno, Elisabetta
Publicado 2023

N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis

por Shahrampour, Shiva, Heholt, Justin, Wang, Andrew, Vedaei, Faezeh, Mohamed, Feroze B., Alizadeh, Mahdi, Wang, Ze, Zabrecky, George, Wintering, Nancy, Bazzan, Anthony J., Leist, Thomas P., Monti, Daniel A., Newberg, Andrew B.
Publicado 2021